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Abstract
PrP has a central role in the Transmissible Spongiform Encephalopathies (TSEs), and mutations and polymorphisms in host PrP can
profoundly alter the host's susceptibility to a TSE agent. However, precisely how host PrP influences the outcome of disease has not been
established. To investigate this we have produced by gene targeting a series of inbred lines of transgenic mice expressing different PrP genes. This
allows us to study directly the influence of the host PrP gene in TSEs. We have examined the role of glycosylation, point mutations,
polymorphisms and PrP from different species on host susceptibility and the disease process both within the murine species and across species
barriers.
© 2006 Elsevier B.V. All rights reserved.
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1. Introduction
The host-encoded protein PrPC has been shown to be
essential for development of a TSE since PrP knock-out mice
are resistant to TSE infection [1,2]. PrP is a glycoprotein
containing two N-glycan attachment sequences (N–X–T) at
amino acids 180 and 196 in mice. These sites are variably
glycosylated in vivo such that un-, mono- and di-glycosylated
glycotypes are observed [3,4]. Both N-glycosylation sites are
conserved in the PrP gene (Prnp) from all species suggesting
that N-glycans may play an important role in the protein
function [5]. A central event in TSEs appears to be a
conformational modification of the normal cellular prion
protein (PrPC) from a soluble form with a predominant alpha-
helical conformation to the disease associated form (PrPSc)
which is rich in beta sheets and partially resistant to proteinase-
K (PK) digestion. Moreover PrPSc has been proposed to be both
the neurotoxic and infectious particle in these diseases, however
the precise form of these particles is still under debate [6].
The host PrP is the most important factor determining the
susceptibility of the host to an infectious TSE agent. However
the mechanism by which susceptibility is determined has not yet
been defined. Mutations in the human PrP gene (PRNP) are
thought to lead directly to disease without the requirement for
an exogenous infectious agent [7,8]. Polymorphisms in PrP
from a number of species are thought to play a role in both the
control of incubation times of disease and host susceptibility
[9,10]. The sequence and structure of PrP in the host and the
donor of infectivity have been hypothesized to influence the
barrier to TSE infection both within and between species with
identity leading to high susceptibility and short incubation times
whereas differences between the proteins are predicted to lead
to longer incubation times and lower susceptibility of the host to
infection [11,12]. The glycosylation of host PrP has been
proposed to be important in the conversion of PrPC to PrPSc and
may be also the factor determining the TSE strain characteristics
and strain targeting in the CNS and in the periphery [13–15].
To clarify the role of host PrP in the disease process we have
developed a number of gene targeted transgenic mouse lines
expressing different PrP genes with specific alterations
introduced into the endogenous murine PrP gene by gene
targeting. We have infected these mice with different TSE
strains to establish the influence of different forms of host PrP in
host susceptibility, the species barrier, and the infectious process
and disease outcome.
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2. Gene targeted transgenic models
Gene targeting allows the generation of transgenic mice that
possess either one or two copies of the desired transgene in the
correct location in the murine genome regulated by the correct
transcriptional controls. Thus the mutated PrP is expressed in
the same tissues and at the same level as that of wild type PrP.
Transgenic mice generated in this way are therefore ideal
models for studying not only the CNS events of disease, but also
for peripheral routes of inoculation to study the disease process
in the periphery.
To produce these mice embryonic stem cells derived from
129/Ola mice are electroporated with a plasmid carrying the
mutated PrP. By homologous recombination the endogenous
murine gene is replaced with the mutated one. These stem cells
are then injected into C57BL mouse blastocysts to produce
chimaeric pups which are then bred with 129/Ola mice to
produce inbred heterozygous and homozygous transgenic lines
carrying the mutated PrP gene. By maintaining inbred lines of
gene targeted mice we have ensured that any alteration in the
disease process and host susceptibility can be directly attributed
to the alteration in the PrP gene [16]. The additional advantage
that this approach gives over the standard production of
transgenic mice is that each of the lines can be directly
compared not only with wild type mice but also with each other.
We have developed transgenic lines to investigate the influence
of point mutations and polymorphisms in host PrP, glycosyla-
tion of PrP and the species of PrP on the host susceptibility and
the TSE disease process.
3. Point mutations in PrP alter incubation time and/or
susceptibility to disease
Several point mutations in PRNP, linked to familial forms of
TSE, have been described and these mutations are thought to
destabilize PrP structure making it more prone to conversion
into the abnormal disease associated isoform, PrPSc, causing the
development of a ‘spontaneous’ TSE disease in the absence of
any exogenous infectious agent [7,8]. Transgenic mice were
produced to model one of these mutations, P102L, which has
been closely linked to the development of Gerstmann–
Straässler–Scheinker (GSS) disease in humans [17]. It was
demonstrated that mice over-expressing the equivalent mutation
in murine PrP (P101L) by 8–16 fold developed a neurological
disease between 150 and 300 days [7]. This spontaneous disease
was moreover transmitted to low copy number 101L transgenic
mice and hamsters, but not to wild type mice [18], thus
suggesting that the P101L mutation in PrP was sufficient to lead
to the development of a TSE. However, gene targeted P101L
transgenic mice have shown that the presence of this disease-
linked mutation alone is not sufficient for the development of a
spontaneous disease since aged gene targeted mice homozygous
for P101L (101LL) did not show any overt phenotype or clinical
signs of TSE. Moreover the brains of these mice were analyzed
for TSE pathology but no vacuolation or PrP deposition was
detected, and no PrPSc was detected by immunoblotting.
Additionally, homogenates of brain and spleen from 101LL
mice over 600 days old have been bio-assayed for the presence
of infectivity by inoculation in 101LL and 101PP mice, but no
infectivity was detectable in these tissues [19] (Barron,
unpublished).
However, despite the absence of a spontaneous disease in
these mice we have shown that this amino acid change in host
PrP can dramatically modify the host susceptibility to TSE
infection [19–21]. Indeed the transgenic mice have different
incubation times of disease compared to wild type animals when
infected with several murine TSE strains (Table 1) and more
dramatically when infected with TSE strains from different
species (human, hamster and sheep). These experiments
suggested that while this mutation in human PrP may not be
sufficient alone to cause disease, it may alter the susceptibility of
the host to disease. This study has also highlighted the
differences obtained in models with physiological and non-
physiological expression levels of PrP in the host. Indeed, a
recent report has suggested that the spontaneous disease in the
standard P101L transgenic mice was due to the level of over-
expression of the P101L PrP, and that the observed transmission
was instead an acceleration of the phenotype already present in
the low level over-expressing transgenic mice [22].
4. PrP sequence identity between host and donor does not
always shorten incubation time
It has been proposed that identity between host PrP and
the PrP sequence of the donor of infectivity is important for
high susceptibility of the host to infection and short in-
cubation times of disease whereas differences in PrP sequence
were proposed to lead to lower susceptibility and longer
incubation times. This was demonstrated in transgenic mice
over-expressing hamster PrP which were shown to be more
Table 1
Incubation times of mouse adapted scrapie strain ME7, 22A, 139A, 79A and BSE derived mouse strain 301V in mice with different genetic combinations at codons
108/189 and 101LL
Mouse line PrP genotype ME7 (i.t.±SEM) 301V (i.t.±SEM) 22A (i.t.±SEM) 139A (i.t.±SEM) 79A (i.t.±SEM)
LT/LT Prnpa(108L-189T) 155±2 240±6 493±6 147±2 139±2
FV/FV Prnp a(108F-189V) 295±7 125±6 227±3 240±2 382±12
LV/LV Prnp a(108L-189V) 261±5 141 NA NA NA
FT/FT Prnp a(108F-189T) 168±1 202±1 NA NA NA
LT/FV Prnpa(108L-189T)/Prnp a(108F-189V) 223±4 202±1 NA NA NA
LV/FT Prnp a(108L-189V)/Prnp a(108F-189T) 265±2 NA NA NA NA
101LL Prnpa101L 338±8 181±1 527±28 306±7 298±3
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susceptible to a hamster strain of scrapie than the wild type
mice [23]. Moreover transgenic mice over-expressing bovine
PrP developed disease rapidly when inoculated with BSE
whereas mice over-expressing a chimaeric bovine/human PrP
were resistant to BSE [24]. This has also been observed
recently in transgenic mice expressing human PrP where
human PRNP 129 heterozygotes were more susceptible to
infection with vCJD than to BSE [25]. Moreover, studies
performed using recombinant PrP have also suggested that
sequence or structural homology may have a profound effect
on TSE susceptibility [26].
Sequence or structural differences between host and donor
PrP are therefore considered to be a possible cause of the species
barrier effect, where long incubation times and low suscept-
ibility are often observed when a TSE strain enters a new
species, followed by a subsequent shortening of incubation time
and increased susceptibility on serial transmission in the new
species [23,27]. However we have demonstrated that replace-
ment of the murine PrP gene with a bovine PrP gene by gene
targeting led surprisingly to longer incubation times for BSE in
the transgenic mice than in the wild type mice despite the
increase in identity between the host and donor PrP in the
transgenic mice. Moreover a similar increase in incubation time
was also observed on inoculation of gene targeted transgenic
mice expressing human PrP with vCJD when compared with
wild type mice, despite again the apparent sequence compat-
ibility [28]. However a number of sCJD strains can transmit
more efficiently to the same human PrP transgenic mouse lines
than to wild type mice, and in this case sequence identity leads
to shorter incubation times and higher susceptibility (Bishop,
unpublished data). Thus while PrP sequence of the host is an
important factor in determining host susceptibility to a TSE
agent it is clearly difficult to predict the transmissibility of a
particular TSE strain in a new host based on the sequence of the
host and donor PrP. Moreover in standard transgenic mice the
expression level of the PrP gene is also likely to determine both
the incubation time and susceptibility of the mice to a particular
agent thus further complicating any studies of host suscept-
ibility in over-expressing mouse lines. Our experiments have
therefore shown that the sequence of PrP has a profound
influence over host susceptibility and incubation time of
disease. However, increasing the sequence homology between
host and donor PrP can increase or decrease incubation time.
The mechanism underlying PrP sequence and host suscept-
ibility therefore still remains to be elucidated and the influence
of other genes and their interaction with PrP yet to be
determined [29–31].
5. Polymorphisms in host PrP are important factors
controlling disease incubation time
While overall sequence identity between host and donor PrP
does not always appear to be a good indicator of incubation time
of disease, are specific mutations or polymorphisms more
critical in determining host susceptibility and incubation time?
Most human TSE strains are difficult to transmit to wild type
mice. However 101LL mice show 100% susceptibility and short
incubation time when inoculated with infected brain homo-
genate from P102L GSS patients [19]. While this may
demonstrate that donor and host identity at 102/101 increase
the efficiency of transmission, a very surprising effect is seen
when these mice are inoculated with experimental sheep scrapie
strain SSBP/1 and hamster scrapie strain 263K. These two
strains, derived from hosts which lacked the corresponding
leucine mutation in PrP, produced shorter incubation times in
the transgenic mice (101LL) than in wild type mice (101PP)
[20]. This point mutation has therefore altered the susceptibility
of the host to TSE agents from three different species and the
mechanism by which this is achieved is not dependent on PrP
sequence compatibility between host and donor.
In order to understand the basis of host PrP sequence and
disease incubation time we have studied the polymorphisms at
amino acids 108 and 189 of murine PrP. Only two PrP alleles
are commonly found in inbred laboratory strains of mice, and
these alleles differ by two polymorphisms: the Prnpa allele
encodes 108L_189T (PrP-A), while Prnpb PrP encodes
108F_189V (PrP-B). All other positions in the two proteins
are identical. It was thought that these polymorphisms were
responsible for the differences in incubation time in PrP-A and
PrP-B mice inoculated with the same strain of agent. However,
due to the different genetic backgrounds of inbred lines
expressing these different alleles, it has been difficult to
determine by classical genetics whether these polymorphisms
do control TSE incubation time in mice [32]. We have produced
a gene targeted transgenic model expressing Prnpa which has
been modified by replacing leucine with phenylalanine at codon
108, and threonine with valine at codon 189 (Prnpa(108F_189V)).
By inoculating these mice with several TSE strains we have
demonstrated that the codon 108 and 189 polymorphisms are
the major factor controlling TSE incubation time in mice [16].
We have also produced and inoculated gene targeted models in
which the codon 108 and 189 polymorphisms have been
introduced separately into the endogenous murine Prnpa gene
producing two unique lines of transgenic mice expressing
Prnpa(108L_189V) and Prnpa(108F_189T). TSE inoculation of
inbred lines of mice expressing all allelic combinations at
codons 108 and 189 has revealed a complex relationship
between PrP allele and incubation time. It has been established
that both codons 108 and 189 control TSE incubation time
(Table 1), and that each polymorphism plays a distinct role in
the disease process. Comparison of ME7 incubation times in
mouse lines that are heterozygous at both codons has also
identified a previously unrecognized intramolecular interaction
between PrP codons 108 and 189 [33].
In humans polymorphisms at codon 129 have been shown to
be important in regulating the susceptibility and phenotype of
TSE disease [9]. In the UK population 40% are homozygous for
methionine (MM), 11% for valine (VV) and 48% are
heterozygous (MV) at this position in Prnp [34]. The majority
of cases of sCJD occur in patients homozygous for Met or Val at
codon 129. Heterozygosity has been reported to lead to
lengthened incubation times in iatrogenic CJD cases associated
with growth hormone treatment, and also in kuru [35,36]. All
instances of clinical vCJD to date have been homozygous for
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methionine at codon 129, and it has been proposed that valine
homozygosity may be protective for both BSE and vCJD
transmission [37]. In order to model human susceptibility to
TSE infection we have produced three lines of gene targeted
transgenic mice expressing human PrP (HuMM, HuVV or
HuMV). Infection of these mice with vCJD was successful in
each case with a gradation of transmission efficiency from MM
to MV to VVand different pathological characteristics for each
genotype (Table 2). The greater transmission efficiency in
HuMM mice suggested that homozygosity for methionine at
codon 129 leads to earlier onset of TSE-related pathological
features and clinical disease than for the other two genotypes.
The differences in PrPSc deposition in the HuMM and HuMV
lines suggest that the codon 129 polymorphism in humans is
likely to affect the distribution of PrPSc deposition in the brain
(Fig. 1). Importantly these studies suggest that all individuals
may be susceptible to vCJD and that subclinical disease may be
extensive particularly in 129MV and 129VV individuals. This
possibility of extensive subclinical disease has also been
highlighted by epidemiological data in humans. A retrospective
tonsil and appendix survey identified appendices from two
129VV individuals which stained positive for PrP accumulation
[38]. Additionally the recent reports of possible human to
human transmission of vCJD by blood transfusion has
identified a 129MV transfusion recipient who had not
developed clinical disease but showed accumulation of PrP in
spleen and lymph nodes at post-mortem [39]. Thus while codon
129 polymorphisms are clearly an important factor controlling
disease susceptibility, pathology and incubation time in human
TSEs, prediction of the outcome of disease with a particular
combination of host genotype and TSE strain is not yet possible.
However a series of further experiments using these unique
humanized transgenic models aims to unravel the rules
governing host susceptibility and risk of disease transmission
in humans.
6. Glycosylation of PrP determines cellular location of PrP
but no overt phenotype occurs in its absence
The prion hypothesis proposes that the TSE infectious agent
is a protease-resistant form of PrP which can self replicate [6].
However the presence of strains of TSE agent with different
incubation times, clinical features and neuropathology [40] has
proved a challenge to this hypothesis. It has been proposed that
Table 2
Incubation times obtained after challenge with vCJD in different lines of transgenic mice expressing human PrP
Transgenic mice
(vCJD inoc)
HuMM KiChM Tg(HuPrP 129M)
35/Prnp0/0
HuMV KiChMV 129MV Tg45/
152 (Prnp0/0)
HuVV KiChVV Tg(HuPrP 129V)
152/Prnp0/0
Reference Bishop et al.,
2006 [28]
Taguchi et al.,
2003 [51]
Asante et al.
2002 [52]
Bishop et al.,
2006 [28]
Asano et al.,
2006 [53]
Asante et al.
2006 [25]
Bishop et al.,
2006 [28]
Asano et al.,
2006 [53]
Hill et al.,
1997 [54]
Codon 129 Met Met Met Met/Val Met/Val Met/Val Val Val Val
Expression level x1 x1 x2 x1 x1 x4–6 x1 x1 x2
Total Affected* 11/17 13/16 14/14 11/16 13/17 15/15 1/16 0/3 25/56
Total affected (%) 65 81 100 69 76 100 6 0 45
* Positive by clinical and/or pathological analysis.
Fig. 1. Different PrPSc deposition in brains of gene targeted mice expressing human PrP with 129MV (A) or 129MM (B) after inoculation with vCJD. HP:
hippocampus; DG: dentate gyrus; TH: thalamus.
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each TSE strain represents a different stable conformation of
abnormal PrP and glycosylation may have an important role in
influencing PrP conformation and determining the strain
characteristics [13,41].
Previous studies performed in vitro indicated that prevent-
ing endogenous PrP glycosylation can alter the structure of
PrP favouring a misfolding process that leads PrPC to acquire
scrapie-like properties [42,43]. This spontaneous conversion
has been also observed in cell cultures treated with
tunicamycin, preventing the attachment of mature sugars at
the Golgi apparatus level [44]. Additionally, accumulation of
N-terminally truncated degradation products has been ob-
served in cell cultures expressing glycosylation-deficient PrP,
supporting the hypothesis that N-glycans function as protein
stabilizers [45]. Thus lack of sugars on PrP may facilitate TSE
onset by inducing PrP to misfold. However, recent data in
transgenic mice over-expressing partially glycosylated PrP
have shown that altered glycosylated PrP has some of the
Table 3
Biochemical characteristics of glycosylation deficient PrP compared with wild
type PrPC (Wt) and with PrPSc from a brain infected with the scrapie mouse
adapted strain ME7
Wt G1 G2 G3 ME7
PK resistance no no no no yes
PIPLC sensitivity yes yes yes yes no
Solubility in 1 M guanidine yes yes yes yes no
Membrane localization in neurons yes yes yes no n.a.
Fig. 2. Localization of Wt PrP (A); G1 PrP (B); G2 PrP (C) and G3 PrP (D) in slides derived from mouse brains. Panel E staining in slides derived from PrP knock out
mice.
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disease associated PrP characteristics such as detergent
insolubility but these proteins maintain the PK sensitivity
similar to wild type PrP [46].
In contrast, biochemical analyses carried out on brains of
our gene targeted transgenic mice expressing mono-glycosy-
lated or un-glycosylated PrP excluded the possibility of
structural changes in PrP when sugars were partially present or
completely absent (Table 3). These transgenic mice have been
generated by substitution of threonine for asparagine180 (G1)
or threonine for asparagine196 (G2) or both mutations
combined (G3), which eliminate the first, second and both
glycosylation sites respectively. The total amount of PrP in the
G1, G2 and G3 lines was similar to that observed in wild type
animals. Un-glycosylated- or mono-glycosylated PrP in vivo
did not display any of the PrPSc characteristics such as PK
partial resistance or insolubility in detergents. Moreover an
ageing experiment carried out in homozygous G3 transgenic
mice further supported these findings as no PK resistant PrP,
glyosis or vacuolation was observed in the brains of G3 mice
over 800 days old [47]. However, sugars may be important in
determining the trafficking of PrPC in neurons. While
transgenic mice expressing mono-glycosylated PrP revealed
similar PrP localization to the wild type protein, with mainly
cell membrane localization and some presence in the
cytoplasm, G3 transgenic mice expressing unglycosylated
PrP showed mainly intracellular localization (Fig. 2).
It has been proposed that accumulation of intracellular PrP
may have a toxic effect causing neurodegeneration, and
transgenic mice expressing cytoplasmatic PrP lacking a GPI
anchor were shown to develop severe ataxia, with cerebellar
degeneration and gliosis [48,49]. However other reports have
shown that accumulation of PrP in the cytoplasm is not toxic
when the cytoplasmatic PrP is expressed under the control of
different promoters [50]. Our mice expressing un-glycosylated
PrP did not develop any type of neurodegeneration during
lifespan suggesting that in this case intracellular accumulation
of a GPI anchored PrP is not toxic.
7. Conclusions
Our studies using gene targeted murine models have
allowed the effect of specific mutations in PrP on host
susceptibility to be examined directly. These studies have
clearly identified that the rules underlying host susceptibility
are considerably more complex than previously proposed. The
amino acid sequence of PrP has a powerful influence on host
susceptibility but although overall identity between host PrP
and PrP from the donor of infectivity often leads to short
incubation times and high host susceptibility the converse can
also be true. Specific mutations and polymorphisms in PrP
clearly have a profound influence on disease incubation time,
host susceptibility and pathogenesis of disease. It has been
proposed that these mutations influence host susceptibility
through their effect on PrP structure but a greater under-
standing of the structural effects of the mutations is required to
establish if this is indeed the case. Our studies with the 108
and 189 polymorphisms suggest interaction between different
parts of the PrP protein appear important in determining host
susceptibility and that different strains of agent interact with
different regions of PrP. Glycosylation of host PrP also
appears from our recent studies to have an important influence
on the outcome of disease (data not shown). However before
we can predict the susceptibility of a host to new TSE strains
we have clearly some way to go in unravelling the mechanism
underlying host susceptibility. We hope, with the use of our
gene targeted models and both in vivo and in vitro studies
derived from these lines of mice, that we will gradually define
these mechanisms and predict host susceptibility to new TSE
strains.
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